Wolfgang Meyer-Sabellek

from Wikipedia, the free encyclopedia
This article is not adequately provided with supporting documents (for example individual proofs ). Information without sufficient evidence could be removed soon. Please help Wikipedia by researching the information and including good evidence.

Wolfgang Meyer-Sabellek (born March 30, 1948 in Tegernsee ) is a German doctor, manager and university professor.

Life

academic career

Meyer-Sabellek attended the Wöhlergymnasium in Frankfurt am Main. After graduating from high school, he studied medicine in Frankfurt am Main from 1967 to 1973 at the Johann Wolfgang Goethe University . In 1975 he received his license to practice medicine and obtained his doctorate in 1977. med. From 1977 to 1979 he carried out research on a grant from the German Research Foundation (DFG) and the Kidney Foundation at the US Medical Center in Los Angeles, Div. of Nephrology, on bone metabolism. After returning to Germany, he worked at the Steglitz University Hospital (today: Charité ) in Berlin from 1979 to 1989 . There he passed the specialist examination (internist and nephrologist ) in 1985, and in 1987 he obtained an additional qualification as a sports medicine specialist . Also in 1987 he received his habilitation from the Free University of Berlin with an examination of indirect 24-hour blood pressure measurement ("Indirect 24-hour blood pressure measurement, examination of the value in the diagnosis and therapy control of arterial hypertension"). Based on the results obtained, in 1989 he initiated the first international consensus conference on “24 h Ambulatory Blood Pressure Monitoring”, which was funded by the ISH, WHL and WHO . In 1990 he was appointed an extraordinary professor by the Free University of Berlin.

In 1994 Meyer-Sabellek became a "Member of the Most Cited Researchers (Science Impact Index = SII)". He was and still is active as a reviewer and advisory board member for numerous scientific institutions, e.g. for the FDA (US Food and Drug Administration: Advisor on Ambulantory Blood Pressure Monitoring / Presenting and Advising strategic clinical research in the Development of new Thrombolytics), for Charité, the German Society for Angiology and for the European Commission . In addition to his activities as a development manager in industry and later as a scientific consultant, Meyer-Sabellek always taught at the Charité, where he also worked scientifically at the Institute for Social Medicine from 2002 to 2009. To this day, Meyer-Sabellek lectures at the Charité and supervises doctoral students.

Manager and development manager

From 1989 to 2007 Meyer-Sabellek worked as a development manager for research, development and approval of new active ingredients in the pharmaceutical industry. At first he headed global clinical development for cardiology and angiology at Boehringer Mannheim , in 1995 he moved to Astra GmbH as Vice President, later AstraZeneca GmbH Germany, where he was Medical Director for the German-speaking region (DACH) and a senior member of the GCRRC (Global Clinical Research) Review Committee) and in the GMDLT (Global Medical Directors Leading Team). As part of his work at Boehringer Mannheim, he was instrumental in the development and global approval of the first double bolus thrombolytic (reteplase), the first β-blocker for the treatment of heart failure ( carvedilol ) and the long-acting loop diuretic ( torasemide ). At Astra and AstraZeneca, as Medical Director for the DACH region , he was in charge of essential parts of the clinical development and approval of drugs in cardiovascular (antihypertensive, lipid-lowering and thrombolytic), gastroenterological and anti-inflammatory indications. In addition, COPD , asthma , oncology and diseases of the central nervous system and bone metabolism were among his areas of work as head of development.

Meyer-Sabellek has been working as a clinical-scientific consultant for pharmaceutical and biotech companies, scientific institutions and university hospitals since 2007 and is in demand. In addition, he continues to perform his duties as a scientific expert and as a university lecturer at the Charité. He is the author and co-author of around 300 scientific publications. Wolfgang Meyer-Sabellek is married and has five children.

Works

  • Indirect 24-hour blood pressure measurement: methodology and clinical significance. Meyer-Sabellek, Wolfgang, W. Meyer-Sabellek and R. Gotzen (Eds.) Darmstadt: Steinkopff, 1988.
  • Blood Pressure Measurement. New Techniques in Automatic and 24-hour Indirect Monitoring. W. Meyer-Sabellek et al. (Hs.), Darmstadt, New York 1990
  • Cancer research - social challenge, Nikolaus-Knoepffler, Dagmar Schimpanski, Otmar D. Wiestler, Ernst-Ludwig Winnacker (eds.), 2008
  • Good Clinical Practice: The 13 GCP standards for investigators to carry out clinical trials taking into account the 12th AMG amendment and the GCP regulation, AstraZeneca (ed.), Authors Wolfgang Meyer-Sabellek, Detlef Geiges, Elfi Schachner-Wünschmann
  • The 23 GCP standards for sponsors to conduct clinical trials: Taking into account the 12th AMG amendment and the GCP regulation, Wolfgang Meyer-Sabellek, Doris Henn, Elfi Schachner-Wünschmann
personal data
SURNAME Meyer-Sabellek, Wolfgang
BRIEF DESCRIPTION German doctor, manager and university professor
DATE OF BIRTH March 30, 1948
PLACE OF BIRTH Tegernsee